Melissa J. Beall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Melissa J. Beall has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Susan E. Little
Department of Veterinary Pathobiology, College of Veterinary Medicine, Oklahoma State University, Stillwater, Oklahoma, USA
7 shared publications - Donato Traversa
Department of Veterinary Medicine, University of Teramo, 64100 Teramo, Italy
4 shared publications - Jesse Buch
IDEXX Laboratories, Inc., Westbrook, ME 04092, USA
4 shared publications - Ramaswamy Chandrashekar
IDEXX Laboratories, Inc., 1 IDEXX Drive, Westbrook, ME 04092, USA
4 shared publications - Anastasia Diakou
School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
3 shared publications - Dwight Douglas Bowman
Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
3 shared publications
Latest Publications
- Open Access
- 10 November 2025
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 27 (11)
Feline leukemia virus lifetime study: whole blood samples increase detection of low positive cats with extended long-term survival
Objectives: Thousands of cats in the USA are newly diagnosed with feline leukemia virus (FeLV) each year, and known FeLV-infected cats are increasingly adopted from shelters. This study investigated optimal sample types to identify FeLV-infected cats and predictors of long-term survival in a cohort of FeLV-positive cats followed for up to 8 years after diagnosis. Methods: Previously, 127 FeLV p27 antigen-positive cats were enrolled in a prospective study. Whole blood, plasma and serum were collected at enrollment and monthly for 6 months. All sample types were tested on SNAP FIV/FeLV Combo Test (SNAP) monthly, and results from microtiter plate ELISA (PetChek) for p27 antigen and a quantitative RT-PCR (qPCR) for proviral DNA were used for confirmation and classification of infection status (high positive, low positive or cryptic/negative). After the 6-month testing phase, cats entered a lifetime survival monitoring phase. Owner-reported status in the current study extended previous survival results by 4 years. Results: Testing anticoagulated whole blood on SNAP at enrollment identified five and nine more FeLV-infected low positive cats (n = 29) than plasma or serum, respectively. Although some low positive (n = 11) cats demonstrated variable test results on SNAP with plasma and serum, others (n = 17) were SNAP positive with all three sample types and classified as low positive based on PetChek and qPCR results. After an additional 4 years of monitoring, low positive cats had not reached a median survival, with 19/29 (66%) cats still alive compared with 2/90 (2.2%) high positive cats. Conclusions and relevance: Anticoagulated whole blood on SNAP was a sensitive indicator of FeLV infection relative to plasma and serum and therefore should be the preferred diagnostic sample for FeLV antigen testing. Combining the results of whole blood antigen testing, PetChek and qPCR identified cats as high positive, low positive or cryptic/negative, with high positive cats having higher risk for early mortality. Use of these diagnostic tools facilitates the management of FeLV as a chronic condition.
- 10 November 2025
- Published by SAGE Publications in Journal of Feline Medicine and Surgery
- Vol. 27 (11)
Open AccessFeline leukemia virus lifetime study: whole blood samples increase detection of low positive cats with extended long-term survival
Objectives: Thousands of cats in the USA are newly diagnosed with feline leukemia virus (FeLV) each year, and known FeLV-infected cats are increasingly adopted from shelters. This study investigated optimal sample types to identify FeLV-infected cats and predictors of long-term survival in a cohort of FeLV-positive cats followed for up to 8 years after diagnosis. Methods: Previously, 127 FeLV p27 antigen-positive cats were enrolled in a prospective study. Whole blood, plasma and serum were collected at enrollment and monthly for 6 months. All sample types were tested on SNAP FIV/FeLV Combo Test (SNAP) monthly, and results from microtiter plate ELISA (PetChek) for p27 antigen and a quantitative RT-PCR (qPCR) for proviral DNA were used for confirmation and classification of infection status (high positive, low positive or cryptic/negative). After the 6-month testing phase, cats entered a lifetime survival monitoring phase. Owner-reported status in the current study extended previous survival results by 4 years. Results: Testing anticoagulated whole blood on SNAP at enrollment identified five and nine more FeLV-infected low positive cats (n = 29) than plasma or serum, respectively. Although some low positive (n = 11) cats demonstrated variable test results on SNAP with plasma and serum, others (n = 17) were SNAP positive with all three sample types and classified as low positive based on PetChek and qPCR results. After an additional 4 years of monitoring, low positive cats had not reached a median survival, with 19/29 (66%) cats still alive compared with 2/90 (2.2%) high positive cats. Conclusions and relevance: Anticoagulated whole blood on SNAP was a sensitive indicator of FeLV infection relative to plasma and serum and therefore should be the preferred diagnostic sample for FeLV antigen testing. Combining the results of whole blood antigen testing, PetChek and qPCR identified cats as high positive, low positive or cryptic/negative, with high positive cats having higher risk for early mortality. Use of these diagnostic tools facilitates the management of FeLV as a chronic condition.
- Open Access
- 15 July 2025
- Published by Elsevier in Veterinary Parasitology
- Vol. 338, 110546
Occurrence of Cystoisospora spp. and other intestinal parasites in dogs and cats with diarrhea
- 15 July 2025
- Published by Elsevier in Veterinary Parasitology
- Vol. 338, 110546
Open AccessOccurrence of Cystoisospora spp. and other intestinal parasites in dogs and cats with diarrhea
- Open Access
- 13 June 2024
- Published by Elsevier in Veterinary Parasitology: Regional Studies and Reports
- Vol. 53, 101061
Performance of a point-of-care test for the detection of anti-Leishmania infantum antibodies is associated with immunofluorescent antibody titer and clinical stage of leishmaniosis in dogs from endemic regions
- 13 June 2024
- Published by Elsevier in Veterinary Parasitology: Regional Studies and Reports
- Vol. 53, 101061
Open AccessPerformance of a point-of-care test for the detection of anti-Leishmania infantum antibodies is associated with immunofluorescent antibody titer and clinical stage of leishmaniosis in dogs from endemic regions
- Open Access
- 5 November 2023
- Published by Elsevier in Veterinary Parasitology
- Vol. 324, 110073
Diagnosis of canine intestinal parasites: Improved detection of Dipylidium caninum infection through coproantigen testing
- 5 November 2023
- Published by Elsevier in Veterinary Parasitology
- Vol. 324, 110073
Open AccessDiagnosis of canine intestinal parasites: Improved detection of Dipylidium caninum infection through coproantigen testing
- Open Access
- 24 August 2023
- Published by Elsevier in Veterinary Parasitology: Regional Studies and Reports
- Vol. 45, 100923
Evaluation of Anaplasma spp. seroprevalence in dogs and association with incidence of human anaplasmosis
- 24 August 2023
- Published by Elsevier in Veterinary Parasitology: Regional Studies and Reports
- Vol. 45, 100923
Open AccessEvaluation of Anaplasma spp. seroprevalence in dogs and association with incidence of human anaplasmosis
- Open Access
- 25 July 2023
- Published by SAGE Publications in Journal of Veterinary Diagnostic Investigation
- Vol. 35 (6) , 671-678
Immunoassay for detection of Dipylidium caninum coproantigen in dogs and cats
Dipylidium caninum infections in dogs and cats are underestimated because of a lack of proglottid observations and poor recovery of parasite elements by centrifugal flotation. We developed an immunoassay that employs a pair of monoclonal antibodies to capture D. caninum–specific coproantigen in fecal extracts from dogs and cats. Real-time PCR for D. caninum DNA in perianal swabs and observation of proglottids were used as reference methods. In 6 experimentally infected dogs, parasite DNA, coproantigen, and proglottid segments were first detected at 22, 23, and 26 d post-infection, respectively. Praziquantel treatment of 3 experimentally infected dogs resulted in the elimination of both coproantigen and proglottid shedding within 1–5 d post-treatment; however, parasite DNA persisted for 14 d. Immunohistochemistry on immature and mature tapeworm segments using an antibody against the coproantigen supports the premise that the antigen is produced in mature segments. We assessed the performance of our coproantigen test in natural infections in 78 dogs from a flea-endemic area. Of the 12 antigen-positive samples, 11 were confirmed with a positive PCR test and/or proglottid observation. Finally, we evaluated a convenience sample set of 730 canine and 163 feline fecal samples obtained from a commercial diagnostic laboratory; D. caninum antigen was detected in 4.1% of the canine and 12.9% of the feline samples, whereas parasite elements were observed in only 0.028% of samples. Our coproantigen immunoassay provides a sensitive method for the detection of D. caninum infection in dogs and cats.
- 25 July 2023
- Published by SAGE Publications in Journal of Veterinary Diagnostic Investigation
- Vol. 35 (6) , 671-678
Open AccessImmunoassay for detection of Dipylidium caninum coproantigen in dogs and cats
Dipylidium caninum infections in dogs and cats are underestimated because of a lack of proglottid observations and poor recovery of parasite elements by centrifugal flotation. We developed an immunoassay that employs a pair of monoclonal antibodies to capture D. caninum–specific coproantigen in fecal extracts from dogs and cats. Real-time PCR for D. caninum DNA in perianal swabs and observation of proglottids were used as reference methods. In 6 experimentally infected dogs, parasite DNA, coproantigen, and proglottid segments were first detected at 22, 23, and 26 d post-infection, respectively. Praziquantel treatment of 3 experimentally infected dogs resulted in the elimination of both coproantigen and proglottid shedding within 1–5 d post-treatment; however, parasite DNA persisted for 14 d. Immunohistochemistry on immature and mature tapeworm segments using an antibody against the coproantigen supports the premise that the antigen is produced in mature segments. We assessed the performance of our coproantigen test in natural infections in 78 dogs from a flea-endemic area. Of the 12 antigen-positive samples, 11 were confirmed with a positive PCR test and/or proglottid observation. Finally, we evaluated a convenience sample set of 730 canine and 163 feline fecal samples obtained from a commercial diagnostic laboratory; D. caninum antigen was detected in 4.1% of the canine and 12.9% of the feline samples, whereas parasite elements were observed in only 0.028% of samples. Our coproantigen immunoassay provides a sensitive method for the detection of D. caninum infection in dogs and cats.
- Open Access
Use of In-Clinic Diagnostic Kits for the Detection of Seropositivity to Leishmania infantum and Other Major Vector-Borne Pathogens in Healthy Dogs
Canine Vector-Borne Diseases (CVBDs) are widespread in Europe and enzootic in many other countries. Though severe illnesses may occur, dogs living in enzootic areas often show vague or no clinical signs of CVBDs. Undiagnosed infections/co-infections in subclinically infected animals favor the spread of CVBDs and increase the risk of transmission to other animals and, in some cases, humans. This study has evaluated the exposure of dogs living in key enzootic countries, i.e., Italy and Greece, to major CVBDs via the use of in-clinic diagnostic kits. Overall, 300 privately owned dogs without/with single mild clinical signs living in different regions of Italy (n. 150) and Greece (n. 150) were included in the study. As part of a clinical examination, a blood sample was collected from each dog and subjected to two serological rapid tests, i.e., the SNAP® 4Dx®Plus (IDEXX Laboratories Inc.) for the detection of antibodies against Ehrlichia spp., Anaplasma spp., Borrelia burgdorferi s.l. and Dirofilaria immitis antigen and the SNAP® Leishmania (IDEXX Laboratories Inc.) for the detection of antibodies against Leishmania infantum. In all, 51 dogs (17%; 95% CI 12.9–21.7) were seropositive to at least 1 pathogen, i.e., 4 in Italy (2.7%; 95% CI 1.4–13.1) and 47 in Greece (31.3%; 95% CI 24–39.4). Dirofilaria immitis antigens were found in 39 dogs (13%; 95% CI 9.4–17.3), while antibodies against Ehrlichia, Anaplasma and Leishmania were detected in 25 (8.3%; 95% CI 5.5–12.1), 8 (2.7%; 95% CI 1.2–5.2) and 5 (1.7%; 95% CI 0.5–3.8) dogs, respectively. None of the dogs tested seropositive for B. burgdorferi s.l. Statistical analyses were performed to evaluate associations between exposure to CVBDs and possible risk factors. The present results indicate that dogs living in enzootic areas may be seropositive for one or more CVBDs in absence of clinical signs. Rapid kits are among first line tools for the detection of CVBDs in clinical settings, as they are cost-effective, straightforward and quick to use. Also, in-clinic tests used herein allowed detection of co-exposure to CVBDs investigated.
Open AccessUse of In-Clinic Diagnostic Kits for the Detection of Seropositivity to Leishmania infantum and Other Major Vector-Borne Pathogens in Healthy Dogs
Canine Vector-Borne Diseases (CVBDs) are widespread in Europe and enzootic in many other countries. Though severe illnesses may occur, dogs living in enzootic areas often show vague or no clinical signs of CVBDs. Undiagnosed infections/co-infections in subclinically infected animals favor the spread of CVBDs and increase the risk of transmission to other animals and, in some cases, humans. This study has evaluated the exposure of dogs living in key enzootic countries, i.e., Italy and Greece, to major CVBDs via the use of in-clinic diagnostic kits. Overall, 300 privately owned dogs without/with single mild clinical signs living in different regions of Italy (n. 150) and Greece (n. 150) were included in the study. As part of a clinical examination, a blood sample was collected from each dog and subjected to two serological rapid tests, i.e., the SNAP® 4Dx®Plus (IDEXX Laboratories Inc.) for the detection of antibodies against Ehrlichia spp., Anaplasma spp., Borrelia burgdorferi s.l. and Dirofilaria immitis antigen and the SNAP® Leishmania (IDEXX Laboratories Inc.) for the detection of antibodies against Leishmania infantum. In all, 51 dogs (17%; 95% CI 12.9–21.7) were seropositive to at least 1 pathogen, i.e., 4 in Italy (2.7%; 95% CI 1.4–13.1) and 47 in Greece (31.3%; 95% CI 24–39.4). Dirofilaria immitis antigens were found in 39 dogs (13%; 95% CI 9.4–17.3), while antibodies against Ehrlichia, Anaplasma and Leishmania were detected in 25 (8.3%; 95% CI 5.5–12.1), 8 (2.7%; 95% CI 1.2–5.2) and 5 (1.7%; 95% CI 0.5–3.8) dogs, respectively. None of the dogs tested seropositive for B. burgdorferi s.l. Statistical analyses were performed to evaluate associations between exposure to CVBDs and possible risk factors. The present results indicate that dogs living in enzootic areas may be seropositive for one or more CVBDs in absence of clinical signs. Rapid kits are among first line tools for the detection of CVBDs in clinical settings, as they are cost-effective, straightforward and quick to use. Also, in-clinic tests used herein allowed detection of co-exposure to CVBDs investigated.
- Open Access
- 28 October 2022
- Published by SAGE Publications in Journal of Veterinary Diagnostic Investigation
- Vol. 35 (1) , 57-61
Evaluation of barcoded magnetic bead–based immunoassays for the simultaneous detection of feline leukemia virus antigen and antibody against feline immunodeficiency virus
Testing platforms that leverage automation, require minimal sample volume, and enable various tests to be performed simultaneously on a single sample have the potential to improve workflow and efficiency in veterinary diagnostic laboratories. We evaluated a barcoded magnetic bead (BMB) technology using established immunoassays for detection of feline leukemia virus (FeLV) p27 antigen and antibody against feline immunodeficiency virus (FIV). Analytical sensitivity, limit of blank, and limit of detection were used to establish a functional sensitivity of 1.00 ng/mL of inactivated FeLV antigen and 35.7 ng/mL of anti-FIV monoclonal antibody. Common interferents, such as hemoglobin, lipid, and bilirubin, were not found to interfere with the performance of the assay. Intra- and inter-assay CVs were <13% for both assays using manufactured samples. Using a set of 116 feline samples, the diagnostic accuracy of our multiplex assay was 100% compared to reference assays. Performance in a convenience set of 1,000 feline samples submitted to a commercial diagnostic laboratory revealed a proportion of positive results of 1.3% for FeLV and 3.7% for FIV. BMB technology should enable rapid screening of samples for various markers in a single immunoassay well.
- 28 October 2022
- Published by SAGE Publications in Journal of Veterinary Diagnostic Investigation
- Vol. 35 (1) , 57-61
Open AccessEvaluation of barcoded magnetic bead–based immunoassays for the simultaneous detection of feline leukemia virus antigen and antibody against feline immunodeficiency virus
Testing platforms that leverage automation, require minimal sample volume, and enable various tests to be performed simultaneously on a single sample have the potential to improve workflow and efficiency in veterinary diagnostic laboratories. We evaluated a barcoded magnetic bead (BMB) technology using established immunoassays for detection of feline leukemia virus (FeLV) p27 antigen and antibody against feline immunodeficiency virus (FIV). Analytical sensitivity, limit of blank, and limit of detection were used to establish a functional sensitivity of 1.00 ng/mL of inactivated FeLV antigen and 35.7 ng/mL of anti-FIV monoclonal antibody. Common interferents, such as hemoglobin, lipid, and bilirubin, were not found to interfere with the performance of the assay. Intra- and inter-assay CVs were <13% for both assays using manufactured samples. Using a set of 116 feline samples, the diagnostic accuracy of our multiplex assay was 100% compared to reference assays. Performance in a convenience set of 1,000 feline samples submitted to a commercial diagnostic laboratory revealed a proportion of positive results of 1.3% for FeLV and 3.7% for FIV. BMB technology should enable rapid screening of samples for various markers in a single immunoassay well.
- Open Access
- 20 October 2022
- Published by Elsevier in Topics in Companion Animal Medicine
- Vol. 51, 100735
An Improved Point-of-Care ELISA for the Diagnosis of Anaplasmosis and Ehrlichiosis During the Acute Phase of Tick-Borne Infections in Dogs
- 20 October 2022
- Published by Elsevier in Topics in Companion Animal Medicine
- Vol. 51, 100735
Open AccessAn Improved Point-of-Care ELISA for the Diagnosis of Anaplasmosis and Ehrlichiosis During the Acute Phase of Tick-Borne Infections in Dogs
- Open Access
A Comparison of Copromicroscopic and Molecular Methods for the Diagnosis of Cat Aelurostrongylosis
The gold standard method for the diagnosis of cat aelurostrongylosis is the detection of Aelurostrongylus abstrusus first stage larvae with the Baermann’s examination. Nevertheless, molecular assays have shown higher diagnostic performances compared to copromicroscopy. This study evaluated the usefulness of an A. abstrusus species-specific PCR on different biological samples collected in clinical settings from 100 privately-owned cats in Italy (n. 60) and Greece (n. 40). A fecal sample was collected from each animal and a pharyngeal swab was also obtained for cats from Italy. All stool samples were subjected to flotation and Baermann’s test. The cats were categorized in three groups based on the results of copromicroscopy, i.e., Group A (n. 50 cats with A. abstrusus infection regardless of positivity for other helminths), Group B (n. 25 cats negative for A. abstrusus but positive for at least one of any other helminth), Group C (n. 25 cats negative for any helminth). DNA was extracted from individual aliquots of feces, flotation supernatant, Baermann’s sediment and the pharyngeal swab and then subjected to a PCR specific for A. abstrusus. At least one fecal aliquot or the pharyngeal swab scored positive by the A. abstrusus-specific PCR for 48/50 (96%) cats enrolled in Group A; in particular, 38/50 (76%), 35/50 (70%), 41/50 (82%) and 21/25 (84%) DNA extracts from feces, flotation supernatant, Baermann’s sediment and pharyngeal swabs were positive by PCR. These results confirm that molecular tools are highly sensitive and specific and indicate that pharyngeal swabs are the most suitable sample for molecular analysis in clinical settings.
Open AccessA Comparison of Copromicroscopic and Molecular Methods for the Diagnosis of Cat Aelurostrongylosis
The gold standard method for the diagnosis of cat aelurostrongylosis is the detection of Aelurostrongylus abstrusus first stage larvae with the Baermann’s examination. Nevertheless, molecular assays have shown higher diagnostic performances compared to copromicroscopy. This study evaluated the usefulness of an A. abstrusus species-specific PCR on different biological samples collected in clinical settings from 100 privately-owned cats in Italy (n. 60) and Greece (n. 40). A fecal sample was collected from each animal and a pharyngeal swab was also obtained for cats from Italy. All stool samples were subjected to flotation and Baermann’s test. The cats were categorized in three groups based on the results of copromicroscopy, i.e., Group A (n. 50 cats with A. abstrusus infection regardless of positivity for other helminths), Group B (n. 25 cats negative for A. abstrusus but positive for at least one of any other helminth), Group C (n. 25 cats negative for any helminth). DNA was extracted from individual aliquots of feces, flotation supernatant, Baermann’s sediment and the pharyngeal swab and then subjected to a PCR specific for A. abstrusus. At least one fecal aliquot or the pharyngeal swab scored positive by the A. abstrusus-specific PCR for 48/50 (96%) cats enrolled in Group A; in particular, 38/50 (76%), 35/50 (70%), 41/50 (82%) and 21/25 (84%) DNA extracts from feces, flotation supernatant, Baermann’s sediment and pharyngeal swabs were positive by PCR. These results confirm that molecular tools are highly sensitive and specific and indicate that pharyngeal swabs are the most suitable sample for molecular analysis in clinical settings.